| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.077 | 0.02 |
| mRNA | CX-5461 | GDSC1000 | pan-cancer | AAC | -0.075 | 0.02 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | -0.1 | 0.02 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.02 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | -0.085 | 0.02 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.03 |